Dogwood Therapeutics, Inc.
SP16 IV
neuropathy and inflammation caused by cancer chemotherapy
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on SP16 IV for neuropathy and inflammation caused by cancer chemotherapy is in focus around Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“Filing the SP16 Chemotherapy Induced Pain and Neuropathy Investigational New Drug application (IND) with FDA in collaboration with our partner, Serpin Pharma, in the first quarter.”